A
Alcista
Alcista · 25%REGN
$785.14
Precio del escenario
$778.360
+26.075 (+3.35%)Al cierre
Loading chart…
- Máximo
- 781.840
- Apertura
- 758.160
- Precio medio ponderado por volumen
- 771.80
- Volumen
- 879.09K
- Capitalización
- 115.79B
- Mínimo
- 755.210
- Importe
- 678.49M
- EV/EBITDA, TTM
- 11.52
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
Análisis de IA of Regeneron Pharmaceuticals Inc (REGN)
ComprarRegeneron Pharmaceuticals Inc is a good buy right now due to its current price of $746.54, which is below the analyst price targets ranging from $737 to $960. The recent expansion of the partnership with Sanofi, which includes a $1 billion upfront payment and potential milestone payments of up to $7 billion, significantly strengthens Regeneron's financial position. Additionally, the company has a strong gross margin of 86.56% in the latest quarter, indicating robust profitability. However, the RSI is at 45.655, suggesting it is nearing oversold territory, which could indicate a potential rebound in price. The main risk is the recent 20-day price change of -4.47%, indicating some volatility in the short term.
Recomendaciones de analistas (26)
+3.87% de potencial alcista
Comprar
13 Comprar
12 Mantener
1 Vender
Actual: 778.36
Mínimo
637.00
Promedio
808.50
Máximo
—
BofA
Comprar
$908
2026-10-12
BofA
2026-10-12
Precio objetivo
$908
Comprar
RBC Capital
Sector Perform
$810
2026-10-08
RBC Capital
2026-10-08
Precio objetivo
$810
Sector Perform
Truist
Comprar
$780
2026-10-07
Truist
2026-10-07
Precio objetivo
$780
Comprar
Morgan Stanley
Equal Weight
$779
2026-10-07
Morgan Stanley
2026-10-07
Precio objetivo
$779
Equal Weight
JPMorgan
Sobreponderar
$950
2026-10-06
JPMorgan
2026-10-06
Precio objetivo
$950
Sobreponderar
Métricas de valoración
El PER previsto actual de Regeneron Pharmaceuticals Inc (REGN) es 14.51, frente a su media de 5 años de 16.97.
Escenarios de precio de Alphio AI para REGN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con REGN en cartera
Cronología de eventos
Noticias
9.010-12stocktwitsRegeneron Reports Positive Phase 3 Trial Results for Pasatru
9.010-12NewsfilterPositive 84-Week Results for Pasatru in FOP Treatment
8.510-03stocktwitsNovartis Partners with Abogen in $7.8 Billion Deal
6.010-01CNBCLatest Wall Street Rating Updates
7.510-01stocktwitsRegeneron Expands Partnership with Sanofi, Secures $1B Upfront
Preguntas frecuentes sobre REGN, respondidas por Alphio AI
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Regeneron Pharmaceuticals Inc is a good buy right now due to its current price of $746.54, which is below the analyst price targets ranging from $737 to $960. The recent expansion of the partnership with Sanofi, which includes a $1 billion upfront payment and potential milestone payments of up to $7 billion, significantly strengthens Regeneron's financial position. Additionally, the company has a strong gross margin of 86.56% in the latest quarter, indicating robust profitability. However, the RSI is at 45.655, suggesting it is nearing oversold territory, which could indicate a potential rebound in price. The main risk is the recent 20-day price change of -4.47%, indicating some volatility in the short term.
26 analysts cover REGN: 13 rate it Buy, 12 Hold and 1 Sell. The average price target is 808.50.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.